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teinuria and, to our knowledge for the first time, show a protec-Crry, a complement regulatory protein, modulates renal inter-
tive role of a complement regulatory protein, Crry, in renalstitial disease induced by proteinuria.
interstitial disease.Background. Recent studies have suggested a role for uri-
nary complement components in mediating tubulointerstitial
damage, which is known to have a good correlation with pro-
gression of chronic renal diseases. Although accumulating evi-
In a variety of kidney diseases, renal prognosis is betterdence suggests that complement regulatory proteins play an
correlated with the structural damage in the tubulointer-important protective role in glomeruli, their role in renal tu-
bules remains unclear. In order to establish the role of a com- stitium than in the glomerulus [1–13]. Accumulating evi-
plement regulatory protein, Crry, in renal tubular injury, we dence suggests that proteinuria is also well correlated
employed a molecular biological approach to block the expres- with tubulointerstitial injury and that proteinuria maysion of Crry in tubules of animals with proteinuria induced
itself be an independent mediator of progression of renalwith puromycin aminonucleoside nephritis (PAN).
Methods and Results. Two different antisense oligodeoxy- diseases [14–20, reviewed in 21–24].
nucleotides (ODNs) against Crry were designed and applied Proteinuria can induce tubulointerstitial injury by sev-
to cultured rat mesangial cells in vitro in order to establish eral mechanisms. High protein concentrations in tubular
their efficacy. Antisense ODN treatment resulted in decreased
fluid, per se, can be toxic to tubular cells by leading toexpression of Crry protein associated with increased sensitivity
lysosomal swelling or obstructing tubules with protein-to complement attack in cell lysis assays compared with control
ODN treatment or no treatment (44.7, 1.50, and 1.34%, respec- aceous casts [25]. Specific proteins that have been re-
tively). Antisense ODNs did not affect the expression of Thy1 ported to be cytotoxic include transferrin [26, 27] and
as a control, confirming the specificity of our ODNs. In vivo, we lipoproteins [28, 29], which can generate oxidants orperformed selective right renal artery perfusion to administer
chemotactic factors. However, recent studies of comple-antisense ODNs to the kidney and showed prominent uptake
ment-depleted rats emphasized roles of complementof ODNs by proximal tubular cells. Reduced expression of
Crry protein was demonstrated in proximal tubular cells in components contained in excessive proteinuria in tubu-
antisense ODNs-treated kidneys. Normal rats treated with the lointerstitial injury [30, 31]. Tubular damage induced
antisense ODNs did not show any pathological changes. How-
chronically by complement activation may result in dete-ever, in PAN, rats with massive proteinuria showed increased
rioration of renal function over time.deposition of C3 and C5b-9 in tubules in antisense-treated
kidneys, and histological assessment revealed more severe tu- The organism has developed a complex system of pro-
bulointerstitial injury in antisense-treated animals compared teins that regulate inappropriate complement activation
with controls. and prevent tissue injury, so-called complement regula-Conclusion. These results establish a pathogenic role for
tory proteins [32–37]. Crry is a rodent complement regu-complement in leading to tubulointerstitial injury during pro-
latory protein that serves the mechanisms of both decay-
accelerating factor (DAF) and membrane cofactor protein
1 See Editorial by Quigg, p. 2315 (MCP) [38, 39]. cDNA of rat Crry was recently cloned
[40, 41]. Proximal tubular cells in rats are endowed withKey words: nephrotic syndrome, antisense oligonucleotides, interstitial
nephritis, progressive renal disease. some complement regulatory proteins, including Crry
[34, 42], although their functional roles remain unclear.
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proach. Our findings provide the first evidence, to our of 2A1 monoclonal antibody to rat C5b-9 have also been
described previously [46]. Polyclonal goat antithymocyteknowledge, that complement regulatory proteins play an
important role in modulating interstitial injury secondary serum (ATS; anti-Thy1) IgG, which was used for comple-
ment-mediated cell lysis assay, was purified using a ca-to proteinuria.
prylic acid precipitation method [47, 48]. For Western
blotting, a hybridoma line producing monoclonal anti-
METHODS
Thy1 antibody (OX-7) was purchased from the Euro-
Mesangial cell culture and transfection pean Collection of Animal Cell Cultures (Porton Down,
Salisbury, UK), and then OX-7 was purified as Yagi etMesangial cells were obtained by culturing glomeruli
isolated from kidneys of 200 to 250 g male Wistar rats al described [49]. Monoclonal antibody against vimentin
(clone V9) was purchased from Dako Corp. (Carpinteria,by a conventional sieving method [43, 44]. The cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) CA, USA).
supplemented with 20% fetal calf serum (FCS) (JRH
Western blot analysisBiosciences, Lenexa, KS, USA), 2 mm l-glutamine, 100
units/ml penicillin, and 100 mg/ml streptomycin (Wako To detect Crry protein, Western blotting was per-
formed using the 5I2 antibody against Crry. MesangialPure Chemical Industries, Osaka, Japan).
Cells were transfected with ODNs as described later cells were washed with phosphate-buffered saline (PBS)
twice and then solubilized for 30 minutes at room tem-in this article using cationic liposomes (LipofectAMINE
Reagent; Life Technologies, Inc., Gaithersburg, MD, perature in cell-solubilizing and reducing buffer. The
protein concentrations of the samples were first mea-USA). In brief, 1.0 3 105 cells per well were seeded in a
12-well tissue culture plate and were incubated until the sured by DC protein assay (Bio-Rad, Hercules, CA,
USA). Ten micrograms of protein were carefully loadedcells were approximately 80% confluent. To allow ODN–
liposome complexes to form, 1.0 mg of ODNs and 8 ml in each lane, and the sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) was performedof LipofectAMINE reagent were combined in 400 ml
serum-free medium and incubated at room temperature under nonreducing conditions. The bound antibody was
detected with 1 mg/ml of alkaline phosphatase-conju-for 30 minutes. Then 400 ml/well of the complex solution
were overlayed onto the cells rinsed with serum-free me- gated antimouse IgG (Promega, Madison, WI, USA).
5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetra-dium. After three hours of incubation, the medium was
replaced with that containing 20% FCS. Forty-eight hours zolium (BCIP/NBT) tablets (Sigma Fast; Sigma Chemi-
cal Co., St. Louis, MO, USA) were used as a substrate.later, the cells were applied to subsequent experiments.
The gel was stained with Commassie brilliant blue, and
Synthesis of oligodeoxynucleotides all of the lanes of the stained gel were confirmed to be
equivalent by visual inspection.Synthetic ODNs employed in this study were designed
from the sequences of the rat Crry [40]. Antisense ODN
Complement-mediated cell lysis assayAS1, consisting of the sequence 59-CAGAGGCGAA
GAAGCCTCCAT-39, was the inverse complement of To determine the functional significance of transfect-
ing cells with the antisense ODNs against Crry cDNA,the positions 24 to 44. Another antisense ODN AS2,
consisting of the sequence 59-TACAAGGCGCCCCA complement-mediated cell lysis assay was performed.
Mesangial cells (approximately 104/cm2) were passagedCGGGGTC-39, was the inverse complement of the posi-
tions 45 to 65. Sense ODN S1 consists of the sequence 59- into 12-well plates and were grown until 50 to 80% con-
fluent. The cells were transfected as described earlier inATGGAGGCTTCTTCGCCTCTG-39. The sequence of
scrambled ODNs based on AS1, SCRA, was 59-GCAA this article, and after 48 hours of incubation, the trans-
fected cells were washed twice with PBS. The nontrans-CACGTATAGGCACGGAC-39. Biotinylated S1, Bio-
S1, was biotinylated on the 59 end of S1. These sequences fected cells that were grown until almost confluent were
used as a control. The cells were sensitized with 300 mldid not show significant homology with any other se-
quences in the nucleic acid sequence database in Gen- of anti-Thy1 (ATS) antibody (2.0 mg/ml) for 20 to 30
minutes at room temperature. After further washing, theBank. These ODNs were synthesized on a PerSeptive
Biosystems synthesizer (PerSeptive Biosystems, Inc., cells were incubated with 400 ml of 5 to 20% rat serum
as a complement source for two hours at 378C togetherFramingham, MA, USA) and were purified over a NAP-
10 column (Pharmacia Biotech AB, Uppsala, Sweden). with DMEM. Cell lysis was quantitated by lactate dehy-
drogenase (LDH) assay kit (Wako Pure Chemical Indus-All of them were phosphorothioated.
tries) as follows: Kinetic determination of LDH was
Antibodies based on the spectrophotometric method of Wroblewski
and LaDue [50]. The activity of LDH was measured byThe characteristics of 5I2 monoclonal antibody to Crry
have been described elsewhere [45]. The characteristics the reductive ability of NADH, which was produced as
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lactate and was oxidized to pyruvate. The background mouse IgG (secondary antibody; Dako Corp.) and Ore-
gon green/Neutralite Avidin (Molecular Probes Inc., Eu-value was estimated using cells incubated with serum
without sensitization. After the assay, all cells were lyzed gene, OR, USA). The fluorescent intensity of C3 staining
was quantitated by computed analysis with the Meta-with 2% Triton X-100 (Sigma Chemical Co.), and the per-
centage of complement-mediated cell lysis was calculated. Morph Imaging System (Universal Imaging Corp., West
Chester, PA, USA). Briefly, the average of the pixel gray
Experimental animals scale values (0 to 4095) contained in the objective was
calculated (S gray scale value/number of pixels). FiveMale Wistar rats weighing 180 to 200 g were purchased
from Nippon Seibutsu Zairyo Center Co., Ltd. (Saitama, randomly selected separate fields of tubulointerstitium
were assessed in each section, and the fluorescence inten-Japan). All animal studies were performed in an accred-
ited animal care facility according to the Guide for Ani- sity was expressed as the mean compensated by back-
ground intensity from nontreated normal rat kidney sec-mal Experimentation, Faculty of Medicine, University
of Tokyo, Tokyo, Japan. tions. C5b-9 deposition was quantitated as the total
number of positive tubules in the four randomly selected
Induction of the puromycin aminonucleoside separate fields of tubulointerstitium in each section.
nephritis model
Histological assessment of tubulointerstitial injuryThe puromycin aminonucleoside nephritis (PAN)
model was induced in rats by single injection of 5 mg/ To examine the renal histology, 4 mm sections of paraf-
fin-embedded tissues were stained with periodic acid-100 g body wt puromycin (Wako) via tail vein.
Schiff reagent (PAS). In each biopsy, the degree of tubu-
Experimental protocol lointerstitial injury was evaluated in a blinded fashion on
the PAS-stained sections. As a semiquantitative analysis,On day 0, puromycin (5 mg/100 g body wt) was injected
into rats. On day 4 when proteinuria had developed, we the total number of the tubules with dilation and degen-
eration, including vacuolar changes, loss of brush border,performed selective right renal artery perfusion through
the superior mesenteric artery with 0.2 mg of antisense detachment of tubular epithelial cells, and condensation
of tubular nuclei, was counted in 10 randomly selectedor sense ODNs in 2 ml of PBS as described previously
[51]. Rats were housed in metabolic cages with free ac- cortical fields (3400) of each section.
cess to water, and urine was collected overnight on days
Measurement of proteinuria and blood urea nitrogen3 and 4, 6 and 7, and 11 and 12 for measurement of
urinary protein. Blood samples were obtained from the Urinary protein excretion of the rats was measured
by DC protein assay (Bio-Rad). Measurement of BUNtail vein on day 7 and via cardiac puncture on day 12
for the measurement of blood urea nitrogen (BUN). On was performed by urease-indophenol method with Urea
N B (Wako Pure Chemical Industries).day 7, a survival right renal biopsy was performed, and
on day 12, a sacrificial right renal biopsy was performed
Statistical analysisfor histological analysis.
All values are presented as mean 6 sd. Statistical
Renal histology and immunohistochemistry comparisons were analyzed with the program StatView
(Abacus Concepts, Berkeley, CA, USA) using the analy-Tissue for frozen sections was embedded in OCT
(Lab-Tek Products; Miles Laboratories, Naperville, IL, sis of variance followed by the Bonferroni/Dunn method
for multiple group comparisons and paired or unpairedUSA) and were snap frozen in acetone in liquid nitrogen.
Frozen sections were stained for Crry and biotinylated Student’s t-test as appropriate. A P value of less than
0.05 was considered statistically significant.ODNs using the Vectastain ABC-AP Kit (Vector Labo-
ratories, Inc., Burlingame, CA, USA) with Vector Red
(Vector Laboratories) as substrate. For vimentin, 4 mm
RESULTS
sections of Methyl Carnoy’s fixed tissue were stained
Expression of Crry protein in transfected mesangialwith clone V9 using a DAB detection system (HistoFine
cells with antisenseSAB-PO Kit; Nichirei, Tokyo, Japan).
To examine the efficacy of our antisense ODNs, we
Immunofluorescence study employed cultured rat mesangial cells, in which the com-
plement-mediated cell lysis assay had been establishedTo examine the tubulointerstitial deposition of com-
plement, 4 mm frozen sections were stained with FITC- [52, 53]. To determine the expression levels of Crry pro-
tein in mesangial cells transfected with ODNs, Westernconjugated goat antibodies against rat C3 (Cappel, Or-
ganon Teknika Corp., Durham, NC, USA) for C3. For blot analysis was performed. The total amount of Crry
was significantly decreased in cells transfected with twoC5b-9, we used a mouse monoclonal antibody 2A1 against
rat C5b-9, which was then detected by biotinylated anti- different antisense ODNs compared with those trans-
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Fig. 1. Western blot analysis comparing the expression
of Crry protein in normal and ODNs-transfected rat
mesangial cells. Rat mesangial cells transfected with anti-
sense ODNs (AS1 and AS2), sense ODNs (S1), scram-
bled ODNs (SCRA), or nontransfected control cells
(control) were examined in order to investigate the effi-
cacy of the ODNs. The total amount of Crry is markedly
decreased in cells treated with AS1 or AS2, compared
with those with S1, SCRA, or control (A). In contrast,
Western blotting with OX-7 revealed an equal amount
of thymocyte antigen between AS1, S1, and control,
ruling out a nonspecific effect of antisense ODNs to
reduce the expression of cellular proteins (B). Similar
results were obtained in four separate experiments.
Markers are expressed in kilodaltons (kD).
fected with sense or scrambled ODNs (Fig. 1A). In con-
trast, Western blotting with OX-7 showed an equal
amount of the thymocyte antigen in antisense ODNs
and sense ODNs-treated cells, ruling out a toxic effect
of antisense ODNs to reduce the expression of cellular
proteins nonspecifically (Fig. 1B).
Augmented complement-mediated cell lysis in
antisense treated cells
Prior to performing a cell lysis assay, the nonspecific
cell toxicity of the ODNs was examined. The superna-
tants of the transfected cells were assessed by measuring
LDH. There was no significant difference among anti-
sense, sense, and scrambled ODNs (data not shown).
To examine the functional characteristics of antisense-
transfected cells, we performed complement-mediated
Fig. 2. Complement-mediated cell lysis assays of oligodeoxynucleo-cell lysis assays. Mesangial cells sensitized with ATS IgG
tides (ODNs)-transfected mesangial cells. Transfected cells were sub-demonstrated cell lysis that was dependent on the con- jected to complement-mediated lysis by treatment of cells sensitized
centrations of rat serum used as a complement source with ATS with 5% normal rat serum as a complement source. This
caused no more than 2.5% cell lysis in untreated mesangial cells (con-as described previously [52, 53]. When sensitized normal
trol). Cell lysis was determined as LDH release after 1.5 hours ofmesangial cells were incubated with 5% normal rat se- incubation at 378C. Note the marked sensitivity of the antisense-treated
cells (AS1) to complement attack compared with sense-transfected cellsrum, no more than 2.5% complement-mediated cell lysis
(S1). *P , 0.05.was observed (1.34 6 1.09%; 4 separate experiments
were performed in triplicate). A decrease of Crry expres-
sion by antisense ODNs was expected to increase sensi-
Uptake of oligodeoxynucleotides in tubular cells bytivity of the cells to complement attack, and we employed
selective renal artery perfusionsublytic conditions using 5% rat serum here. Sensitized
mesangial cells transfected with AS1 were much more In previous studies, the administration of ODNs via
susceptible to complement attack than controls trans- the circulation resulted in the localized deposition of ODNs
fected with S1 (AS1, 44.7 6 6.89%; S1, 1.50 6 1.47%, in proximal tubules [54–57]. To ensure this localization,
we performed selective right renal artery perfusion withP , 0.05; Fig. 2).
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Fig. 3. Uptake of ODNs in tubular cells at 4
and 24 hours after selective renal artery perfu-
sion. Biotinylated sense ODNs, Bio-S1 (0.2
mg), were perfused in normal rat kidney and
biopsies were obtained 4 and 24 hours later.
Uptake of Bio-S1 at both intervals was con-
fined primarily to proximal tubules. Staining
was not observed in other segments of neph-
ron. (3200)
Fig. 4. Reduced expression of Crry protein
in proximal tubular cells transfected with anti-
sense ODNs. In three days after the selective
right renal artery perfusion, Crry was not de-
tectable in proximal tubules in the kidneys
perfused with 0.2 mg of AS1 (A), whereas
sense-perfused samples (B) did not show any
changes of Crry expression levels, compared
with sections of untreated control kidneys (C).
The expression levels of Crry in antisense
treated kidneys returned to normal seven days
after the treatment (D). (3200)
biotinylated ODNs, Bio-S1. Bio-S1 (0.2 mg) was perfused
in normal rat kidneys, and biopsies were obtained 4 and
Table 1. Urinary protein excretion and blood urea nitrogen (BUN) 24 hours later. Proximal tubular cells were positive forin antisense and sense groups of PAN rats
ODNs deposition in four hours, whereas glomerular cells
Antisense (AS1) Sense (S1) t-test and other segments of the nephron were negative (Fig. 3).
Day 7 At 24 hours, the level of staining remained high in proxi-
Urinary protein mg/day 44.9614.7 31.7614.5 NS mal tubular cells.BUN mg/dl 18.762.06 17.461.45 NS
N 14 13 —
Day 12 Reduced expression of Crry protein in proximal
Urinary protein mg/day 124633.8 105633.6 NS tubular cells by antisense oligodeoxynucleotides
BUN mg/dl 25.762.34 20.562.03 NS
N 11 9 — To determine the effect of antisense ODNs on the
Data are mean 6 sd. NS is not significant. expression of Crry protein in vivo, selective right renal
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Fig. 5. Immunofluorescence findings. Depo-
sition of rat C3 (top panels) and C5b-9 (bot-
tom panels) in antisense (A and C) and sense
(B and D) treatment in PAN rats is shown.
Deposition of rat C3 and C5b-9 mainly along
the luminal side of proximal tubules was
clearly demonstrated in antisense-treated kid-
neys at day 7 (A) and at day 12 (C) in contrast
to control sense-treated kidneys at day 7 (B)
and at day 12 (D), respectively. (3400)
artery perfusion of ODNs was performed in normal rats. compared with sections of untreated control kidneys
(Fig. 4). The expression levels of Crry in antisenseAntisense ODNs (AS1) and sense ODNs (S1; 0.02, 0.06,
and 0.2 mg) were perfused. Careful examinations of the treated kidneys returned to normal seven days after the
perfusion (Fig. 4).biopsy samples stained by PAS and hematoxylin and
eosin (HE) revealed no significant pathological changes
Augmented tubulointerstitial injury by antisensein either group, and we decided to use 0.2 mg of ODNs
oligodeoxynucleotides against Crry in PAN ratsin the following studies, expecting the maximal effects
without nonspecific damage on tissues. Immunohistolog- Induction of the PAN model. To evaluate whether
ical analysis with monoclonal antibody against Crry, 5I2, or not tubulointerstitial injury associated with massive
revealed that Crry was not detectable in proximal tubules proteinuria was affected by proximal tubule localization
in the kidneys perfused with 0.2 mg of AS1 at one day of antisense ODNs against Crry, we used the PAN model
of nonimmunologically-induced nephrotic syndrome. Onand three days, whereas sense perfused samples at any
dose did not show any changes in Crry expression levels day 4, no rats developed proteinuria. On day 7, urinary
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quantitated. The intensity of fluorescence for C3 was
significantly increased in the antisense-treated kidney
sections both on day 7 and on day 12 as compared with
those of sense (AS1 and S1 treated at day 7, 1070 6 39.1
and 698 6 37.5, respectively, P , 0.05; AS1 and S1
treated at day 12, 1040 6 51.0 and 676 6 33.7, respec-
tively, P , 0.05; Fig. 6A). C5b-9 deposition was quanti-
tated as the total number of positive tubules in four
separate fields of tubulointerstitium in each sample. The
number of C5b-9–positive tubules was also increased in
the antisense groups on day 7 and day 12 as compared
with sense groups (Fig. 5b), although the difference be-
tween the two groups reached statistical significance only
at day 7 (AS1 and S1 treated at day 7, 20.8 6 4.63 and
6.08 6 2.72, respectively, P , 0.05; AS1 and S1 treated
at day 12, 12.7 6 2.73 and 7.00 6 1.54, respectively, P 5
0.10; Fig. 6B).
PAS staining. Histological assessment of tubulointer-
stitial injury was performed with PAS staining. Tubules
with dilation and/or degeneration, including tubular hya-
line casts, loss of brush border, and detachment of tubu-
lar epithelial cells from basement membrane, were more
often observed in antisense-treated kidneys compared
with control sense-treated kidneys (Fig. 7a). Semiquanti-
tative analysis revealed that the extent of tubular dilation
and/or degeneration was more severe at both day 7 and
day 12 in antisense groups (AS1 and S1 treated at day
Fig. 6. Quantitative analysis of C3 and C5b-9 deposition in antisense-
7, 15.7 6 2.02 and 7.15 6 0.876, respectively, P , 0.05;or control sense-treated kidneys of PAN rats. The degree of C3 deposi-
tion was quantitated by computed analysis. C5b-9 deposition was quanti- AS1 and S1 treated at day 12, 15.5 6 1.64 and 7.33 6
tated as the total number of positive tubules in four separate fields of 1.31, respectively, P , 0.05, Fig. 7b).
tubulointerstitium in each sample. The intensity of fluorescence for C3
Vimentin staining. Vimentin staining was performed(A) was significantly increased in the antisense (AS1)-treated (j) kid-
ney sections on day 7 and day 12 as compared with those of sense (S1; as another indicator of tubulointerstitial injury. More
h). Also, the number of C5b-9 (B)-positive tubules was remarkably vimentin-positive tubules were observed in tubules inincreased in antisense groups (j) on day 7 and day 12 as compared
the cortex at day 7 and day 12 in the antisense-treatedwith sense groups (h). *P , 0.05.
rats than in the control animals, although the difference
between the two groups did not reach statistical signifi-
cance (AS1 and S1 treated at day 7, 18.5 6 5.93 and
protein levels in the antisense group and sense group 6.77 6 3.22, respectively, P 5 0.10; AS1 and S1 treated
were 44.9 6 14.7 and 31.7 6 14.5 mg/day, respectively at day 12, 20.4 6 4.43 and 10.6 6 3.43, respectively,
(P . 0.1), and on day 12, 124 6 33.8 and 105 6 33.6 P 5 0.10). Staining for vimentin in glomeruli and renal
mg/day, respectively (P . 0.1; Table 1). Therefore, the vasculature was identical in the two groups.
amount of complement components in urine was as-
sumed to be similar in both groups. Also, BUN was in
DISCUSSIONthe normal range at day 7 and at the upper limit of
normal at day 12 in both groups, with no significant Although structure–function correlations between dis-
turbances in glomerular structure and kidney failure aredifference (P . 0.1; Table 1). For immunohistochemical
and histological analysis, the number of rats in each relatively imperfect [2, 3], distinct relationships between
tubulointerstitial damage and impairment of kidney func-group was as follows: antisense group at day 7 and day
12, N 5 14 and N 5 11, respectively; sense group at day tion have been well established [1, 4–13]. The cause of
progressive loss of renal function by tubulointerstitial in-7 and day 12, N 5 13 and N 5 9, respectively.
Immunohistological findings. Immunofluorescence jury is likely to be multifactorial. Tubular atrophy may lead
to a reduction in the glomerular filtration rate (GFR)study revealed the strong deposition of C3 in cortical
tubules on day 7 and on day 12 in the antisense groups through tubuloglomerular feedback by increasing fluid
delivery to the macula densa [7]. Interstitial fibrosis mayas compared with control sense groups (Fig. 5a). By
computed analysis, the degree of C3 deposition was occlude postglomerular capillaries and reduce glomerular
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Fig. 7. Histological assessment of tubuloin-
terstitial injury. (a) PAS staining of antisense-
(A and C ) or sense- (B and D) treated kidney
at day 7 (A and B) and at day 12 (C and D)
in PAN rats. Tubules with dilatation and/or
degeneration were more often observed in
antisense-treated kidneys compared with con-
trol sense-treated kidneys (3200). (b) Semi-
quantitative analysis of tubulointerstitial in-
jury. The extent of tubular dilatation and/or
degeneration was significantly more severe in
the antisense groups both at day 7 and day
12 as compared with control sense groups.
Symbols are: (j), antisense (AS1)-treated;
(h), sense (S1)-treated. *P , 0.05.
blood flow [6]. Tubular damage may cause atubular glo- cytoskeletal alterations and the generation of inflamma-
tory mediators, which may contribute to tubulointersti-meruli and a decrement in the number of functional
nephrons [58, 59]. tial damage [65]. Micropuncture studies demonstrating
that inactivation of complement prevented proximal tu-Considerable evidence suggests that proteinuria itself
may give rise to tubulointerstitial injury, serving as an bular lesions induced by intraluminal perfusion with se-
rum [66] supported this hypothesis. Recent articles byindependent mediator of progression of chronic renal
failure [reviewed in 21–24]. One of the potential mecha- Morita et al and Nomura et al clearly established the
pathogenic role of complement components in protein-nisms by which proteinuria causes tubulointerstitial ne-
phritis is activation of complement components contained uric urine. Complement depletion with cobra venom fac-
tor or inhibition with recombinant soluble human com-in proteinuric urine [30, 31]. Although complement com-
ponents are not filtered by glomeruli under normal con- plement receptor type 1 dramatically ameliorated tubu-
lointerstitial injury induced by proteinuria in rats withditions, their presence has been demonstrated in the
urine of patients with nephrotic syndrome [60, 61]. These aminonucleoside nephrosis or with mesangial prolifera-
tive glomerulonephritis [30, 31].complement components are contained in massive pro-
teinuria deposits on renal tubules [62] and may be acti- Although important roles of complement regulatory
proteins in glomerular cells have been well establishedvated by the brush border, which was shown to activate
the alternative pathway directly [63, 64]. Complement [52, 53, 67–73, reviewed in 74], their roles in tubular
cells remain to be determined. We hypothesized thatactivation on the tubular epithelial surface can result in
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complement regulatory proteins in renal tubular cells of PAN rats was more severe in the antisense-treated
animals (Figs. 5 and 6). Histological analysis demon-might protect tubules from attack by complement com-
ponents derived from proteinuric urine. To investigate strated that the more severe complement deposition was
associated with profound tubulointerstitial damage inthe role of one complement regulatory protein, Crry, in
tubules, we employed antisense ODNs to reduce Crry PAN rats treated with antisense ODNs (Fig. 7). These
histological assessments were confirmed by staining forexpression [75–79]. Recent kinetic studies showed that
when phosphorothioated ODNs were administered sys- vimentin, a marker of renal tubular injury. Vimentin,
a member of the family of intermediate filaments, istemically, a major portion of the dose was taken up by
the proximal tubules in the kidney [80–82]. Furthermore, expressed in glomeruli and renal vasculature, but not in
tubular cells, in normal rats [86]. Alterations seen inelectrophoresis of the isotope-labeled ODNs adminis-
tered intravenously showed that ODNs retained intact damaged tubules, regardless of etiology, include a neoex-
pression of vimentin [86, 87]. PAN rats treated within the kidney for at least four days after infusion [54, 55].
These studies strongly suggest that the kidney, especially antisense ODNs showed more vimentin-positive tubules
(Fig. 7). The amounts of proteinuria in antisense-treatedrenal tubules, is an ideal target for in vivo antisense ODN
experiments. We ensured the specific localization of animals and in control rats were not statistically different,
implying that the differences in tubular complement de-ODNs by selective right renal artery perfusion with bio-
tinylated ODNs (Fig. 3). position and tubulointerstitial damage were specific con-
sequences of the decrease in Crry expression and conse-To examine the efficacy and specificity of the antisense
ODNs, we performed in vitro experiments utilizing cul- quent increased complement activation.
While PAN rats treated with antisense ODNs showedtured rat mesangial cells first. Mesangial cells were suit-
able for this purpose because they constantly express more severe tubulointerstitial damage than those treated
sense ODNs, the two groups of animals did not show anyCrry protein on the cell membrane [42, 70], and comple-
ment-mediated cell lysis assays to investigate the func- difference in renal function despite distinct relationships
between tubulointerstitial damage and impairment oftional consequences of the antisense ODNs have been
well established in these cells [52, 53]. Western blot anal- kidney function established in previous human studies
[1, 4–13]. This may be explained by the relatively shortysis and complement-mediated cell lysis assays clearly
demonstrated the specificity and functional efficacy of observation period in our studies (12 days) in contrast
to the clinical studies demonstrating a significant correla-our antisense ODNs (Figs. 1 and 2).
tion between tubulointerstitial injury and a loss of renalPrevious immunohistochemical studies as well as our
function during the follow-up of years or decades.study demonstrated expression of Crry in tubular cells
In conclusion, the decrease in Crry expression in proxi-in rats [42]. Our in vivo antisense treatment by selective
mal tubules induced by the antisense ODN approach wasrenal artery perfusion successfully decreased Crry ex-
shown to induce significant activation of the complementpression in proximal tubules (Fig. 4). However, a reduc-
cascade on the brush border of proximal tubules, leadingtion in Crry expression levels in normal rats did not induce
to tubulointerstitial injury in proteinuric rats. Our studiesany pathological changes in our studies. In contrast, No-
confirm a pathogenic role for complement componentsmura et al exquisitely demonstrated a role of Crry in pre-
contained in proteinuria leading to tubulointerstitial in-venting tubular injury by inducing tubulointerstitial dam-
jury and, to our knowledge for the first time, documentage utilizing renal artery perfusion of anti-Crry antibody
a protective role for a complement regulatory protein,into normal rat kidneys [83]. This discrepancy may be ex-
Crry, in renal tubular cells.plained by a predominant effect of anti-Crry administration
on vascular Crry. As anti-Crry antibody could bind to the
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